Agreements

Vivalis has signed an EB66® cell line research license agreement with one the world’s largest human vaccine developers. The scope of this agreement is for the evaluation of the use of the EB66® cell line for the production of several vaccines in development and for vaccines currently commercialized, where the switch to the EB66® cell line would represent a replacement substrate for previously approved products. This agreement represents the fourth EB66® cell line agreement signed since the start of the 2013 calendar year.